Differences

This shows you the differences between two versions of the page.

--- workvafin2 [2020/12/30 20:46] – [Example 3: Diabetes study] mestebanm
+++ workvafin2 [2020/12/30 21:14] (current) – [Results and interpretation] mestebanm
@@ Line 34: / Line 34: @@
 When the analysis is finished at Hipathia web, the report/results will be available in “My studies” section once the study is done.\\  You can download any table or image showed in the report page by clicking on the name right before it.\\ You can also download the circuit activity values and function matrices by clicking on //Circuit values//, //GO terms values// and //Uniprot keywords values// respectively.
-As we can see in the figure below, the results after simulation the KO of gene RAP1GAP over the 54 non diabetic samples only show deregulation on the pathways where the gene RAP1GAP can be found. Since RAP1GAP is an inhibitor of the Rap1 pathway, mostly all the functions associated to the circuits that compose the pathway are UP-regulated. The functional consequences of the KO of RAP1GAP vary from UP-regulation of Inflammatory processes, Cell adhesion, Stress response among others. The results shown seem to indicate that RAP1GAP plays an important role in the control of these processes.
+As we can see in the figure below, the results after the simulating the KO of gene RAP1GAP over the 54 non diabetic samples only show deregulation on the pathways where the gene RAP1GAP can be found. Since RAP1GAP is an inhibitor of the Rap1 pathway, mostly all the functions associated to the circuits that compose the pathway are UP-regulated. The functional consequences of the KO of RAP1GAP vary from UP-regulation of Inflammatory processes, Cell adhesion and Stress response among others. The results shown seem to indicate that RAP1GAP plays an important role in the control of these processes highly related to diabetes. Therefore, loss of function mutations in those genes inactivating RAP1 protein would most likely result in an over-activation of inflammatory response and thus, an increased risk of developing immune-mediated diabetes ([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908734/|Peña-Chilet et al., 2019]]).
 {{ ::rap1_signaling_pathway_hsa04015_1_.svg.png?nolink |}}